EpiPen Maker Mylan Is Airing Fewer Commercials for Its Pricey Product
Posted in: Uncategorized
Amid the rising controversy surrounding price increases to $600 or more for its allergy-combatting EpiPen, owner Mylan has drastically decreased the frequency of airings of its “Face Your Risk” commercial, according to research compiled for Ad Age by media research firm iSpot.tv.
The 30-second spot, which debuted as part of a larger campaign in late April, features a terrifying scene in which a woman with a peanut allergy accidentally eats a peanut-butter-filled brownie at a party. Since the spot is filmed from the perspective of the victim, viewers see the horrified expressions of other partygoers before glimpsing the bloated and blotchy face of the allergy sufferer in a mirror. Interestingly, the spot makes no mention of the EpiPen, but directs consumers to an awareness website which then leads to a separate EpiPen information website.
Mylan has spent $14.7 million running the ad44% of the company’s total 2016 TV spending so far this year — on the campaign, according to iSpot. The ad ran 326 times the week of July 31. Yet in recent weeks, as the public outcry against Mylan has grown, the spots are appearing less often. Mylan ran the commercial 292 times the week of Aug. 7, 66 times the week of Aug. 14, and has only aired it twice in the last four days, iSpot found.
Post a Comment